Targeting voltage-gated calcium channels: developments in peptide and small-molecule inhibitors for the treatment of neuropathic pain.
about
Bioactive Mimetics of Conotoxins and other Venom PeptidesFrom foe to friend: using animal toxins to investigate ion channel functionN-type calcium current, Cav2.2, is enhanced in small-diameter sensory neurons isolated from Nf1+/- mice.Effects of arginine 10 to lysine substitution on ω-conotoxin CVIE and CVIF block of Cav2.2 channels.Inhibition of A-type potassium current by the peptide toxin SNX-482Spinal blockage of P/Q- or N-type voltage-gated calcium channels modulates functional and symptomatic changes related to haemorrhagic cystitis in mice.Transient receptor potential ion channels in primary sensory neurons as targets for novel analgesics.Management of cancer pain: 1. Wider implications of orthodox analgesics.New investigational drugs for the treatment of neuropathic pain.Therapeutic conotoxins: a US patent literature survey.Surfen is a broad-spectrum calcium channel inhibitor with analgesic properties in mouse models of acute and chronic inflammatory pain.Involvement of ion channels and transporters in carcinoma angiogenesis and metastasis.Injury-induced maladaptation and dysregulation of calcium channel α2 δ subunit proteins and its contribution to neuropathic pain development.Inhibition of N-type calcium channels by fluorophenoxyanilide derivatives.Homology-guided mutational analysis reveals the functional requirements for antinociceptive specificity of collapsin response mediator protein 2-derived peptides.Sodium hydrosulfide relieves neuropathic pain in chronic constriction injured rats.Cisplatin alters the function and expression of N-type voltage-gated calcium channels in the absence of morphological damage of sensory neurons.Mechanisms for therapeutic effect of bulleyaconitine A on chronic pain
P2860
Q26778961-A985D021-C96E-40DF-A4DA-3DEE9094C939Q26864410-499643BB-C155-4804-A94D-3D86BA371B94Q33822127-F3A24F58-99C8-474C-9AA5-5965FC17AFB2Q33842774-7A2B2C88-345F-4EFE-A351-FE6C3CABC809Q33865281-AC20D399-B024-4358-BB18-E7D33F2E2027Q34994554-D3A616C8-128C-4AA9-A9A0-DE76D1583557Q38166804-7A319859-52CC-4393-B476-7C28A888C068Q38182562-6A5DF7BB-3B13-443C-8302-08990BEAEEACQ38217614-3255B1A7-885F-41D7-BE34-1EF82FAB4663Q38525254-FFC3694C-DB87-4569-8BFD-EB4A5AE4FDBBQ38701037-26E1D7D7-D86A-44D3-B49C-8E5D85480DFCQ38704738-EC449190-8137-41A4-BEBF-F699501ECB6AQ38711009-097021B9-6261-4DF9-9D34-5A6CA8F3D332Q38887632-CBD63F7D-5EAE-41A7-9A1D-5F83199912B9Q40349390-EA13C313-59DC-4395-BB30-5237FB2FBF25Q42541859-EE30DFAE-F62C-496E-9251-EDB2697D857EQ47153113-91657A1D-3BA3-4434-94C9-42214B829B04Q58763314-716BC7C2-4BFA-41CE-864B-0F67C053EF8D
P2860
Targeting voltage-gated calcium channels: developments in peptide and small-molecule inhibitors for the treatment of neuropathic pain.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Targeting voltage-gated calciu ...... treatment of neuropathic pain.
@en
type
label
Targeting voltage-gated calciu ...... treatment of neuropathic pain.
@en
prefLabel
Targeting voltage-gated calciu ...... treatment of neuropathic pain.
@en
P2860
P1476
Targeting voltage-gated calciu ...... treatment of neuropathic pain.
@en
P2093
P2860
P304
P356
10.1111/J.1476-5381.2012.02082.X
P407
P577
2012-11-01T00:00:00Z